Cervilenz Boosts Series A to $8.35M

Cleveland-based Cervilenz has added to its Series A round, closing the round with $8.35 million. The company, backed by investors including Arboretum Ventures and Chrysalis Ventures, plans to use the funding to continue commercialization of its medical devices for women. The device is designed to predict the risk of preterm birth in pregnant women.